What to Consider When Designing Drug-dosing Regimens

Video

Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, explains how changes in antimicrobial resistance should be reflected in drug dosage.

Elizabeth Dodds-Ashley, PharmD, MHS, at the Department of Medicine at Duke University School of Medicine, explains how changes in antimicrobial resistance should be reflected in drug dosage.

Interview Transcript (slightly modified for readability)

“Certainly, [the] pharmacodynamics [of a drug] are considered when drug-dosing regimens are initially designed. I think that, maybe, where we’re not spending as much time is on things that have evolved over time, [such as] some older antibiotics that are now being used to treat very resistant infections that were never around when the drugs were first studied; [consequently], maybe those doses are not the right doses anymore, although they were right initially, when the drugs were first released.

I think that it’s something that is hard and challenging to put into front-line providers’ day-to-day drug prescribing, but something that certainly should be considered on a more global perspective. [That way], when we have particular resistance data for a patient and there’s a particularly resistant pathogen, we take that into account to get the dose correct.”

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.